Transfusion medicine

QuidelOrtho Reports First Quarter 2024 Financial Results

Retrieved on: 
Mercredi, mai 8, 2024
Biotechnology, Health, Data Management, Technology, Health Technology, EDT, EVP, PDT, Conference, Webcast, COVID-19, EPS, Transfusion medicine, QuidelOrtho, GAAP, Interest, Online shopping

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first quarter ended March 31, 2024.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first quarter ended March 31, 2024.
  • The decrease in total revenue was primarily due to lower COVID-19 revenue in the first quarter of 2024 compared to the prior year period.
  • Foreign currency translation did not significantly impact first quarter 2024 results.
  • QuidelOrtho will hold a conference call today at 2:00 p.m. PDT / 5:00 p.m. EDT to discuss its financial results for the first quarter ended March 31, 2024.

QuidelOrtho Appoints Brian J. Blaser as President and Chief Executive Officer

Retrieved on: 
Jeudi, mai 2, 2024
Communications, Health, Manufacturing, Other Health, Other Manufacturing, Public Relations, Investor Relations, Advisory Council, University, Bangladesh Technical Education Board, Laboratory, Johnson & Johnson, Trustee, Kodak, Abbott Laboratories, Ortho Clinical Diagnostics, Mechanical, Growth, General Motors, Transfusion medicine, Multimedia, QuidelOrtho, MBA, Management

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point of care settings, clinical labs and transfusion medicine, announced the Company’s Board of Directors (the “Board”) has appointed Brian J. Blaser as President and Chief Executive Officer (“CEO”) effective May 6.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point of care settings, clinical labs and transfusion medicine, announced the Company’s Board of Directors (the “Board”) has appointed Brian J. Blaser as President and Chief Executive Officer (“CEO”) effective May 6.
  • View the full release here: https://www.businesswire.com/news/home/20240502548327/en/
    “We are excited to welcome Brian as our new president, CEO and director,” said Kenneth F. Buechler, Ph.D., Chairman of the Board.
  • “I am honored and excited to join QuidelOrtho as president and CEO during this pivotal point in the Company’s journey.
  • The Company’s commitment to customer service and its dedication to improving healthcare outcomes align closely with my own values,” said Brian J. Blaser, President and CEO, QuidelOrtho.

QuidelOrtho To Report First Quarter 2024 Financial Results

Retrieved on: 
Mercredi, avril 17, 2024
Health, Hospitals, Health Technology, Other Health, General Health, Biotechnology, Transfusion medicine, Webcast, QuidelOrtho, Conference, Interest, Online shopping

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today it will report its financial results for its first quarter ended March 31, 2024, after the market close on Wednesday, May 8, 2024.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today it will report its financial results for its first quarter ended March 31, 2024, after the market close on Wednesday, May 8, 2024.
  • Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m.
  • ET to discuss its financial results.
  • Interested parties can access the call on the “Events & Presentations” section of the “Investor Relations” page of the Company’s website at https://ir.quidelortho.com/ .

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Retrieved on: 
Mardi, mars 19, 2024
Medical Supplies, Biotechnology, Practice Management, Other Health, Health, General Health, Health Technology, Medical Devices, Hospitals, Surgery, Clinical Trials, Red blood cell, STARS, Platelet, SPARC, Incidence, AKI, Patient, Corporation, Mitt, News, CERS, RBC, Acute kidney injury, Clinical trial, Antibody, Transfusion medicine, PMA, Safety, DSMB, Data, Food, FDA, Physician, Cerus Corporation, Pharmaceutical industry

Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients.
  • There was no clinical significance related to treatment-emergent RBC antibodies observed in five patients receiving INTERCEPT RBCs.
  • This safety endpoint is also being explored in the Company’s ongoing RedeS Phase 3 clinical trial of INTERCEPT RBCs.
  • “We are extremely pleased by the positive topline results of the ReCePI clinical trial,” stated Richard Benjamin, M.D., Ph.D., Cerus’ chief medical officer and principal investigator for the ReCePI clinical trial.

QuidelOrtho Receives Health Canada Approval for Quidel® Triage® PLGF Test for Laboratory Use in Canada

Retrieved on: 
Mercredi, mars 6, 2024
Data Management, Biotechnology, Baby, Maternity, Technology, Other Health, Health, Women, Health Technology, Medical Devices, Consumer, Clinical Trials, Pre-eclampsia, Eclampsia, Woman, Transfusion medicine, QuidelOrtho, Health Canada, Quality, Premature, Pregnancy, Risk, Diagnosis, Quality control, Safety, Prognosis, Biomarker, Lancet, Triage, Stillbirth, Guideline, HELLP, Placenta, Plasma, HELLP syndrome, Placentation, Medical device

QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada.
  • The Triage PLGF test is a fluorescence immunoassay to be used with the small footprint Triage MeterPro® Instrument for the quantitative determination of placental growth factor (“PLGF”) in maternal plasma specimens.
  • With the Triage PLGF test, clinicians can be positioned to better detect angiogenic imbalance and assess the risk for these complications.
  • The Triage PLGF test is available to customers in Canada for use with the Triage MeterPro instrument.

QuidelOrtho to Participate in 45th Annual Raymond James Institutional Investor Conference

Retrieved on: 
Lundi, février 26, 2024
Biotechnology, Finance, Health, Medical Devices, Data Management, Health Technology, Professional Services, Technology, Interim, Transfusion medicine, Conference

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced that members of its management team are scheduled to participate in the 45th Annual Raymond James Institutional Investor Conference on March 5, 2024, in Orlando, FL.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced that members of its management team are scheduled to participate in the 45th Annual Raymond James Institutional Investor Conference on March 5, 2024, in Orlando, FL.
  • Recently named Interim Chief Executive Officer, Michael Iskra, and Interim President, Robert Bujarski, will join Chief Financial Officer, Joseph Busky, in a brief presentation followed by a fireside chat at 4 p.m.
  • ET / 1 p.m. PT.

QuidelOrtho Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Mardi, février 13, 2024
Health, Hospitals, Health Technology, Other Health, General Health, Biotechnology, Transfusion medicine, QuidelOrtho, Immunohaematology, Growth, GAAP, COVID-19, Labs, EPS

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the fourth quarter and full-year ended December 31, 2023.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the fourth quarter and full-year ended December 31, 2023.
  • GAAP diluted EPS for the fourth quarter of 2023 was $0.10, compared to $0.45 in the prior year period.
  • GAAP operating income for the fourth quarter of 2023 was $40 million, compared to $87 million in the prior year period, and GAAP operating margin was 5% in the fourth quarter of 2023, compared to 10% in the prior year period.
  • Adjusted EBITDA for the fourth quarter of 2023 was $195 million, compared to $245 million in the prior year period.

QuidelOrtho to Report Fourth Quarter and Full-year 2023 Financial Results

Retrieved on: 
Mardi, janvier 23, 2024
Software, Biotechnology, Pharmaceutical, Health, Data Management, Health Technology, Technology, Clinical Trials, QuidelOrtho, Transfusion medicine, Interest, Conference, Webcast, Online shopping

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Tuesday, February 13, 2024.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Tuesday, February 13, 2024.
  • Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m.
  • ET to discuss its financial results.
  • Interested parties can access the call on the “Events & Presentations” section of the “Investor Relations” page of the Company’s website at https://ir.quidelortho.com/ .

Blood Community Unites to Recognize Donors Ahead of National Blood Donor Month in January

Retrieved on: 
Mercredi, décembre 20, 2023
Veteran, Bleeding, Disaster, Trauma, Food, ABC, Bone marrow, Transplant, Plasma, Blood transfusion, Blood, Hospital, Cancer, American Red Cross, Transfusion medicine, Volunteering, AABB, Ice, Patient, Organization, Accreditation, Medical device

This month serves to recognize America’s donors and encourage more individuals to donate blood in January and throughout the year.

Key Points: 
  • This month serves to recognize America’s donors and encourage more individuals to donate blood in January and throughout the year.
  • “National Blood Donor Month is a time to recognize the selfless contributions of the roughly 7 million people across the country who give blood each year.
  • “This National Blood Donor Month, the blood community says thank you to the millions of blood donors throughout the United States.
  • This month continues to be celebrated each year to thank America's blood donors and encourage more people to donate blood.

New York Blood Center Enterprises Makes Investment to Advance Next-Generation Red Blood Cell Research

Retrieved on: 
Jeudi, décembre 7, 2023
SCD, Sickle cell disease, Research development, Research, Health, Doctor of Philosophy, Education, Genetic disorder, Transfusion medicine, Public, Patient, Intelligence, Organization, Nursing

BOSTON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises ( NYBCe ) announced today that its venture fund, NYBC Ventures , has invested in Functional Fluidics to advance research in sickle cell disease and transfusion medicine.

Key Points: 
  • BOSTON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises ( NYBCe ) announced today that its venture fund, NYBC Ventures , has invested in Functional Fluidics to advance research in sickle cell disease and transfusion medicine.
  • Functional Fluidics , a CLIA-certified diagnostics laboratory specializing in red blood cell health, will use the funds to expand its services to Africa and develop the next generation of red blood cell health assays with the potential to improve diagnostic outcomes in sickle cell disease (SCD), transfusion medicine, and other hematological disease areas.
  • SCD is a globally prevalent genetic disorder that affects more than 100,000 Americans and more than 7 million people worldwide.
  • The investment in Functional Fluidics research is the latest effort in the organization’s mission to expand its humanitarian impact on global public health.